Lusutrombopag(Mulpleta)

Lusutrombopag manufactured by Lucius Pharmaceuticals is an oral thrombopoietin receptor agonist with favorable efficacy and safety, providing a convenient treatment option for preoperative platelet management in patients with chronic liver disease.

Overview of the Main Information of Lusutrombopag.

Active Ingredient

The main active ingredient is lusutrombopag, with a content of 3mg per tablet.

Indicated Population

It is indicated for adult patients with chronic liver disease complicated by thrombocytopenia who are scheduled to undergo surgery.

Dosage and Administration

The recommended dose is 3mg orally once daily for 7 consecutive days, and the surgery should be performed within 2-8 days after the last dose.

Medication in Special Populations

Pregnant women should use the drug after weighing the benefits and risks; lactating women should suspend breastfeeding during medication; the safety of pediatric use has not been established; and the medication data in elderly patients is limited.

Drug Overdose

Drug overdose may lead to excessive elevation of platelets and increase the risk of thrombosis. Close monitoring and symptomatic treatment are required.

Drug Storage

The drug should be stored in its original packaging at room temperature and kept out of reach of children.

Pharmacokinetics

Lusutrombopag is slowly absorbed after oral administration, with a half-life of approximately 27 hours, and is mainly excreted via feces.

FDA，2018.07